Elon Musk’s Neuralink trials pave way for a brain-computer interface breakthrough

Neuralink, a brain implant company founded by Elon Musk, is seeking participants worldwide for a clinical trial that aims to allow individuals to control a computer with their minds. The company is recruiting participants with spinal cord injuries resulting in quadriplegia or amyotrophic lateral sclerosis (ALS).

On April 2, Neuralink stated on X that it required more patients to volunteer for a clinical trial known as Precise Robotically Implanted Brain-Computer Interface (PRIME). This six-year clinical trial involves a small device that can decode human brain signals to operate devices. As of January, three quadriplegic patients have been able to be implanted with the device and are currently testing the capabilities of the implant.

🌎 The Neuralink Patient Registry is now open globally!

If you have quadriplegia and are interested in exploring groundbreaking ways to control a computer using your thoughts, you can now sign up from anywhere in the world.https://t.co/jdKOJNhuKf pic.twitter.com/rgG1sRr8G7

— Neuralink (@neuralink) April 2, 2025

Neuralink aims to improve the quality of life for the disabled and help them communicate and move around more freely. The participants will have the device implanted using a robotic-assisted surgical procedure as described on Neuralink’s website. Once the interface is inserted, the person can control computers and smartphones with their mind.

Neuralink’s first patient says he had no side effects

Recently, Noland Arbaugh, the first person to have Neuralink’s device implant, said he had no adverse effects. The quadriplegic patient who had the implant in early 2024 said that the device has positively affected his life. 

Through the implant, Noland can now perform numerous tasks. He spends over 10 hours daily controlling a computer cursor, playing games, browsing, or even socializing. Arbaugh also disclosed that Neuralink is planning to support the capability of controlling a wheelchair.  

However, he asserts that the technology needs to be refined before it can be widely implemented, stating, “I won’t use it unless it’s next to perfect. I think it benefits everyone if I don’t lose control and drive into traffic.”

Beyond personal use, Arbaugh attributed the implant to his ability to work as a traveling keynote speaker, writer, researcher, and communicator. He shared his optimism regarding BCIs, stating that the number of implant recipients will increase from the current few tens to hundreds and even thousands.

Musk talks about future brain chip enhancements

In a recent Tesla all-hands meeting, Musk discussed Neurolink’s long-term plan, even stating that future iterations may be able to install a chip into the brain to tweak people’s cognitive and sensory abilities. He has hinted at potential “cybernetic augmentation” that may put advanced tools inside human beings to give them enhanced vision and mind.

.@elonmusk: “Long term we will also have enhancement of humans … If somebody wants to have cybernetic enhancements … we could absolutely provide superhuman abilities via Neuralink in the future.” pic.twitter.com/A42LHCGrOS

— Chief Nerd (@TheChiefNerd) March 21, 2025

In 2024, Neuralink applied for a trademark on a product called ‘Telepathy,’ which allows people to think and control gadgets. The company is also experimenting with new products and technologies, such as the Blindsight device, which helps those with serious vision impairment regain their sight. 

China’s brain-computer interface efforts gain momentum

Neuralink is experiencing stiffer competition in the brain-computer interface (BCI) market. More recently, CIBR, a Chinese research institute, partnered with NeuCyber NeuroTech to start tests of its own brain chips. 

The Chinese team plans to implant the Beinao No.1 into 13 patients by 2025, according to Reuters. This could, in effect, assist CIBR in outperforming Neuralink’s inpatient data enrollment, making it a strong contender in the field.

Synchron, an American BCI company, is another reputed entity currently pioneering clinical trials across the United States and Australia. Synchron has garnered support from well-known investors like Jeff Bezos and Bill Gates, adding more competitive pressure to Neuralink even more cutthroat as the field advances.